DNA-PK inhibitors and uses thereof
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
1. A method of potentiating a therapeutic regimen for the treatment of breast cancer, colorectal cancer, gastric-esophageal cancer, fibrosarcoma, glioblastoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, melanoma, lung cancer, pancreatic cancer, or prostate cancer in a patient comprising the step of administering to said patient an effective amount of a compound or a pharmaceutical composition comprising said compound, wherein the compound is
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the compound is represented by the following formula:
6. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the compound is represented by the following formula:
11. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
12. The method of claim 1 , wherein the compound is represented by the following formula:
or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the pharmaceutical composition is orally administered to the patient.
14. The method of claim 1 , wherein the pharmaceutical composition is a capsule, tablet, or aqueous suspension.
15. The method of claim 14 , wherein the pharmaceutical composition is a capsule.
16. The method of claim 14 , wherein the pharmaceutical composition is a tablet.
17. The method of claim 1 , wherein the therapeutic regimen comprises radiation therapy.
18. The method of claim 1 , wherein the therapeutic regimen comprises an anti-cancer therapeutic agent.